The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages
Open accessAbstract
The peroxisome proliferator-activated receptors (PPARs) are a family of fatty acid-activated transcription factors which control lipid homeostasis and cellular differentiation. PPARalpha (NR1C1) controls lipid oxidation and clearance in hepatocytes and PPARgamma (NR1C3) promotes preadipocyte differentiation and lipogenesis. Drugs that activate PPARalpha are effective in lowering plasma levels of lipids and have been used in the management of hyperlipidemia. PPARgamma agonists increase insulin sensitivity and are used in the management of type 2 diabetes. In contrast, there are no marketed drugs that selectively target PPARdelta (NR1C2) and the physiological roles of PPARdelta are unclear. In this report we demonstrate that the expression of PPARdelta is increased during the differentiation of human macrophages in vitro. In addition, a highly selective agonist of PPARdelta (compound F) promotes lipid accumulation in primary human macrophages and in macrophages derived from the human monocytic cell line, THP-1. Compound F increases the expression of genes involved in lipid uptake and storage such as the class A and B scavenger receptors (SRA, CD36) and adipophilin. PPARdelta activation also represses key genes involved in lipid metabolism and efflux, i.e. cholesterol 27-hydroxylase and apolipoprotein E. We have generated THP-1 sublines that overexpress PPARdelta and have confirmed that PPARdelta is a powerful promoter of macrophage lipid accumulation. These data suggest that PPARdelta may play a role in the pathology of diseases associated with lipid-filled macrophages, such as atherosclerosis, arthritis, and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is likely reasoned by the abundant expression of PPARd, a hallmark of THP-1 cell differentiation (Vosper et al., 2001) (Supplemental Fig. 16).”
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, the PPARd activation promotes lipid accumulation in THP-1 macrophages in the presence of serum (Vosper et al., 2001).”
The cited source says what the claim attributes to it.
In the citing paper
“As we did not use any lipoproteins as stimulus, the studies of Vosper et al. (2001) on PPARd and lipid accumulation in macrophages most accurately resemble our experimental setup.”
The cited source says what the claim attributes to it.
In the citing paper
“In line with our findings, the treatment with a PPARd agonist upregulated the expression of genes involved in lipid metabolism, including CD36 and PLIN2, in this study.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,564
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
FORMAN, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,857
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H.-W., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,861
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomázy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,815
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,746
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,303
Flagged first, then by citations
Research works printed but not linked: 3
- Cullen, 1987, Methods Enzymol., 152, 692
- Wu, 1994, Mol. Cell. Biol., 14, 2129
- Kang, 1997, Mutat. Res., 382, 57
Cited by
Sorted by citations
Items 201–270 of 270
Ligand‐activated interaction of PPARδ with c‐Myc governs the tumorigenicity of breast cancer
Ham, S. A., Kim, E., Yoo, T., Lee, W. J., Youn, J. H., Choi, M., Han, S. G., Lee, C., Paek, K. S., Hwang, J. S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31864 · Cited by 14
A Role for PPARβ/δ in Ocular Angiogenesis
Bishop‐Bailey, D. (2008) · PPAR Research · doi:10.1155/2008/825970 · Cited by 12
Liu, M., Yang, W., Liu, S., Hock, D., Zhang, B., Huo, Y. R., Tong, X., & Yan, H. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2017.1288740 · Cited by 12
Dyrøy, E., Røst, T. H., Pettersen, R. J., Halvorsen, B. L., Gudbrandsen, O. A., Ueland, T., Muna, Z. A., Müller, F., Nordrehaug, J. E., Aukrust, P., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255950.70774.d5 · Cited by 12
Physiological ligands of PPARs in inflammation and lipid homeostasis
Lathion, C., Michalik, L., & Wahli, W. (2006) · Future Lipidology · doi:10.2217/17460875.1.2.191 · Cited by 12
Generation and characterization of a humanized PPARδ mouse model
Gross, B. S., Hennuyer, N., Bouchaert, E., Rommens, C., Grillot, D., Mezdour, H., & Staels, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01359.x · Cited by 11
Chehaibi, K., Hrira, M. Y., Rouis, M., Najah, M., Jguirim-Souissi, I., Nouira, S., & Slimane, M. N. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-9997-4 · Cited by 11
Weerakkody, T. N., Sabelström, H., Andrews, S. V., Chadarevian, J. P., Chin, M. Y., Tatarakis, D., Propson, N. E., Kim, D. J., Theolis, R., Parico, G. C. G., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adw7428 · Cited by 12
Metabolic Regulation of T Cell Immunity
Vignali, P., Barbi, J. J., & Pan, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_2 · Cited by 10
Unique Mode of Lipogenic Activation in Rat Preputial Sebocytes
Deplewski, D., Qin, K., Ciletti, N. A., & Rosenfield, R. L. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/163631 · Cited by 10
Leiguez, E., Giannotti, K. C., Viana, M. D. N., Matsubara, M. H., Fernándes, C. M., Gutiérrez, J. M., Lomonte, B., & Teixeira, C. (2018) · Mediators of Inflammation · doi:10.1155/2018/2547918 · Cited by 10
Yamazaki, Y., Ogawa, S.-I., & Shibuya, K. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.049 · Cited by 9
Tanigawa, K., Hayashi, Y., Hama, K., Yamashita, A., Yokoyama, K., Luo, Y., Kawashima, A., Maeda, Y., Nakamura, Y., Harada, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249184 · Cited by 9
Distinct Roles of PPARs in Atherosclerosis
Wang, G., Yan, Y. K., Sun, Q., Chen, L., Qiang, L., & Liu, L. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322198 · Cited by 8
Kluge, S., Schubert, M., Börmel, L., & Lorkowski, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158875 · Cited by 10
Khazaei, M., Salehi, E., Rashidi, B., Javanmard, S. H., & Fallahzadeh, A. R. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.02.005 · Cited by 8
An in vitro model of adipose tissue-associated macrophages
Bhatia, K., Tiwari, S., Gupta, V. K., Sapariya, N. M., & Upadhyay, S. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00464-5 · Cited by 8
Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis
Gross, B. S., Fruchart, J., & Staels, B. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.08.009 · Cited by 7
Luo, W., Chen, F., Guo, Z., Wu, M., Zhou, Z., & Yao, X. (2015) · Annals of Human Biology · doi:10.3109/03014460.2015.1023847 · Cited by 5
Drug discovery in the metabolic syndrome: context and some recent developments
Suckling, K. E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.801 · Cited by 5
Self-citationPPARs: Important Regulators in Metabolism and Inflammation
Sanderson, L. M., & Kersten, S. (2010) · Springer eBooks · doi:10.1007/978-90-481-3303-1_10 · Cited by 4
Gliclazide inhibits differentiation-associated biologic events in human monocyte-derived macrophages
Mamputu, J., Li, L., & Renier, G. (2006) · Metabolism · doi:10.1016/j.metabol.2006.01.015 · Cited by 4
Cohen, R. A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000137187.16206.79 · Cited by 4
Zhong, Y., Zhu, X.-M., Li, J.-C., Sheng, L.-S., Qi, J.-Y., Shen, X.-H., Du, H., Huang, N.-N., & Sun, R. (2026) · Chinese Medicine · doi:10.1186/s13020-025-01310-y · Cited by 3
Avila, G. M., Ceciliani, F., Viala, D., Dejean, S., Sala, G., Lecchi, C., & Bonnet, M. (2024) · Journal of Proteomics · doi:10.1016/j.jprot.2024.105232 · Cited by 3
Pineda‐Torra, I., Fruchart, J., & Staels, B. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_21 · Cited by 3
Lahiri, S., & Wahli, W. (2010) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.076 · Cited by 3
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_14 · Cited by 3
Receptores activados por proliferadores peroxisómicos y aterosclerosis
Carrera, M. V. (2002) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(02)78879-7 · Cited by 2
Endocrine and Paracrine Factors in Carcinogenesis
Heber, D., & Cohen, P. (2006) · Elsevier eBooks · doi:10.1016/b978-012088393-6/50069-5 · Cited by 2
Tung, Y., Lyu, K.-N., Chen, Y.-C., & Chien, Y. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.11.010 · Cited by 2
Kim, J.-B., Lee, S. H., Ahn, J., & Kim, J. (2012) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2012.1.1.11 · Cited by 2
Nuclear receptors: novel therapeutic targets for the treatment and prevention of atherosclerosis
Hanniman, E. A., & Sinal, C. J. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.08.008 · Cited by 2
Scott, J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000067043.83862.57 · Cited by 2
Nitric oxide-independent lipid metabolism in RAW 264.7 macrophages loaded with oleic acid
Huang, W. C., & Chen, J. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.06.014 · Cited by 1
Lipid Regulation with Niacin Extended-Release (Niaspan-R™)
Vosper, H. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s5155 · Cited by 1
Self-citationLlaverı́as, G., Lacasa, D., & Alegret, M. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78949-4 · Cited by 1
Macrophage Lipid Uptake and Foam Cell Formation
de Villiers, W. J. S., & van der Westhuyzen, D. R. (2003) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-55742-2_9
Mitchell, C. S., & Gurnell, M. (2006) · Advances in molecular and cellular endocrinology · doi:10.1016/s1569-2566(06)05002-2
Chapter 3 PPARδ: Emerging therapeutic potential of novel agonists in lipid and glucose homeostasis
Dressel, U., & Muscat, G. E. O. (2006) · Advances in molecular and cellular endocrinology · doi:10.1016/s1569-2566(06)05003-4
PPAR‐Based Therapies for the Management of Atherosclerosis
Gizard, F., & Pineda‐Torra, I. (2010) · Atherosclerosis · doi:10.1002/9783527629589.ch6
Plutzky, J. (2008) · Wiley eBooks · doi:10.1002/9783527610754.md05
Viñals, M., Bermúdez-Escobar, I. C., & Laguna, J. C. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78960-3
Efectos complementarios de las terapias farmacológicas
Ribalta, J. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78972-x
Gregoire, F. M. (2008) · PPAR Research · doi:10.1155/2008/736362
Cabrero, À., Cubero, M., Llaverı́as, G., Jové, M., Planavila, A., & Vázquez‐Carrera, M. (2004) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(04)78969-x
The Prevention of Atherothrombotic Events in Adults with Acute Coronary Syndromes
Vosper, H. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s6639
Self-citationEstudo do controle traducional de PPAR durante o processo de diferenciação de macrófagos
Cambiaghi, T. D. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2010.tde-25032010-145009
Signaling in the Cardiovascular System
Simon, M. C., Liu, L., Barnhart, B. C., & Young, R. M. (2008)
ReviewArticle Macrophages, PPARs, and Cancer
Ginderachter, J. A. V., Movahedi, K., den Bossche, J. V., & BAETSELIER, P. D. (2008)
Retinoic acid in adipocyte biology
Berry, D. C. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Ding, X., Yuan, H., Gu, R., Gao, Y., Liu, X., & Gao, Y. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8597085
Boucher, P., & Vogel, H. G. (2015) · Springer eBooks · doi:10.1007/978-3-642-27728-3_53-1
Mathisen, R. (2004) · NORA - Norwegian Open Research Archives
Anti-atherogenic actions of dihomo-gamma-linolenic acid in macrophages
Gallagher, H. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Mitochondrial Function in Cell Growth and Death
(2004) · Springer eBooks · doi:10.1007/0-306-48529-x_5
Fontaine, C., Duval, C., Barbier, O., Chinetti, G., Fruchart, J., & Staels, B. (2003) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(03)33026-7
Boucher, P., & Vogel, H. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-05392-9_53
Bojic, L. A. (2013) · Scholarship@Western (Western University)
Lipid-gene interactions, diet and health
Lairon, D., & Planells, R. (2006) · Elsevier eBooks · doi:10.1533/9781845691073.1.49
IRF5 and the metabolic adaptations of adipose tissue macrophages upon metabolic stress
Orliaguet, L. (2022) · theses.fr (ABES) · doi:10.70675/145b35eazd61az4b32zacc7z422afeae6061
Immune-Mediated Endothelial Injury in Cardiometabolic–Cardiovascular Disease
Wang, Q., Liu, L., Li, W., & Li, Y. (2026) · Biomedicines · doi:10.3390/biomedicines14112415
Efecte de l'activació de PPARβ/δ sobre l'oxidació d'àcids grassos i el procés inflamatori
Barroso, E. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The role of PPARalpha and growth hormone in hepatic lipid metaboism and atherosclerosis
Ljungberg, A. (2006) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Metadata
- Authors
- Vosper, H., Patel, L., Graham, T. L., Khoudoli, G. A., Hill, A., Macphee, C. H., Pinto, I., Smith, S. A., Suckling, K. E., Wolf, C. R., & Palmer, C. N. A.
- Affiliations
- Ninewells Hospital (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Palmer, Colin N.A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 276
- Issue
- 47
- Pages
- 44258-44265
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2103618523
- Cited by
- 268
- References
- 49
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 7 · 2017: 7 · 2016: 6 · 2015: 7 · 2014: 2 · 2013: 10 · 2012: 7
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Funders
- British Heart Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARδ, peroxisome proliferator-activated receptors, macrophage lipid accumulation, macrophage differentiation, compound F, scavenger receptors, CD36, adipophilin, apolipoprotein E, lipid metabolism, atherosclerosis, THP-1 cells
- MeSH terms
- Animals, Cell Line, Cholesterol, Gene Expression Regulation, Humans, Macrophages, Transcription Factors, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
